{
    "clinical_study": {
        "@rank": "51892", 
        "acronym": "MIM", 
        "arm_group": {
            "arm_group_label": "Imatinib", 
            "arm_group_type": "Experimental", 
            "description": "an adaptation strategy of dosage of Imatinib Mesylate versus a standard strategy"
        }, 
        "brief_summary": {
            "textblock": "The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with\n      CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response\n      and major molecular response rate) is dependent on the residual plasma Imatinib."
        }, 
        "brief_title": "Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Leukemia, Myeloid, Chronic-Phase", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Leukemia, Myeloid, Chronic-Phase"
            ]
        }, 
        "detailed_description": {
            "textblock": "The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with\n      CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response\n      and major molecular response rate) is dependent on the residual plasma Imatinib. This study\n      aims to evaluate the effectiveness of a strategy for dose adjustment of Imatinib Mesylate\n      based on the measurement of the residual plasma imatinib in patients treated for at least 2\n      years Imatinib 400 mg / d in complete cytogenetic response for at least 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with CML-CP treated for at least two years by Imatinib Mesylate 400 mg / d,\n\n          2. Patients in complete cytogenetic response for at least 1 year\n\n          3. Patients with residual disease detectable by quantitative RT-PCR (RQ-PCR)\n\n          4. ECOG \u2264 2,\n\n          5. Age \u2265 18 years\n\n          6. Signed informed consent,\n\n          7. Membership of a social security system\n\n        Exclusion Criteria:\n\n          1. Patients with CML-CP Philadelphia chromosome negative diagnosis.\n\n          2. Patients previously treated with Imatinib Mesylate at doses above 400 mg / day\n\n          3. Patient with non-hematologic toxicity of grade III or IV in Imatinib Mesylate 400mg /\n             d\n\n          4. Patient with a medical condition endocrine, psychiatric, neurological, renal, hepatic\n             or cardiac progressive uncontrolled by medical treatment\n\n          5. Pregnant or breastfeeding women, women of childbearing potential not using a\n             contraceptive method effective\n\n          6. Known HIV positive\n\n          7. Patients previously treated with another tyrosine kinase inhibitor\n\n          8. Patient participating in another interventional clinical trial\n\n          9. History of non-compliance to Imatinib Mesylate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "268", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01827930", 
            "org_study_id": "IB2009-07"
        }, 
        "intervention": {
            "arm_group_label": "Imatinib", 
            "description": "Imatinib Mesylate LMC", 
            "intervention_name": "Imatinib Mesylate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Imatinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "chronic myeloid leukemia in chronic phase", 
        "lastchanged_date": "April 9, 2013", 
        "link": {
            "description": "Site internet du promoteur, l'Institut Bergoni\u00e9", 
            "url": "http://www.bergonie.org/fr/essais-clinique.html"
        }, 
        "location": {
            "contact": {
                "last_name": "ETIENNE Gabriel, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Bordeaux", 
                    "country": "France", 
                    "state": "Aquitaine", 
                    "zip": "33000"
                }, 
                "name": "Institut Bergoni\u00e9"
            }, 
            "investigator": {
                "last_name": "ETIENNE Gabriel, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of IM on the Molecular Response in Patients With LMC in Chronic Phase Treated With IM 400 mg / Day for at Least Two Years, Complete Cytogenetic Response for at Least One Year", 
        "overall_contact": {
            "email": "g.etienne@bordeaux.unicancer.fr", 
            "last_name": "ETIENNE Gabriel, MD"
        }, 
        "overall_contact_backup": {
            "email": "s.mathoulin@bordeaux.unicancer.fr", 
            "last_name": "MATHOULIN PELISSIER Simone, PU-PH"
        }, 
        "overall_official": {
            "affiliation": "Institut Bergoni\u00e9", 
            "last_name": "ETIENNE Gabriel, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compare the effectiveness of a strategy to adapt dosage of Imatinib Mesylate (based on residual plasma IM), the effectiveness of a standard (IM fixed dose of 400 mg / day )", 
            "measure": "Compare the effectiveness of a strategy to adapt dosage of Imatinib Mesylate (based on residual plasma IM), the effectiveness of a standard (IM fixed dose of 400 mg / day )", 
            "safety_issue": "No", 
            "time_frame": "07/2013 (up to 12 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01827930"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluate the rate and time to reach the complete molecular response at 6, 9 and 12 months Evaluate the rate and time to reach the major molecular response at 6, 9 and 12 months Evaluate the rate and time to obtain a first rate BCR-ABL undetectable at 6, 9 and 12 months Evaluate overall survival and progression-free survival at 12 months To evaluate the safety of the IM.", 
            "measure": "Evaluate the rate and time to reach the complete molecular response at 6, 9 and 12 months", 
            "safety_issue": "No", 
            "time_frame": "07/2013 (6, 9, and 12 months)"
        }, 
        "source": "Institut Bergoni\u00e9", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut Bergoni\u00e9", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2009", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}